Aspira Pathlab & Diagnostics MD, chairman, board of directors and AGM
BSE: 540788Healthcare ServicesSmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹123.45.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹130 Cr3,082nd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 23 May 2026
- 10.6
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 12 Aug 2026
- −3.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 12 Aug 2026
- −4.4%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 23 May 2026
- 0.11
- Volume, BSEVolume. Shares traded on the last trading day.
- 352
Aspira Pathlab & Diagnostics board of directors
At the end of the quarter to Sep 2026, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonHaseeb Ahmad Drabu
- Managing directorNikunj Velji Mange
5 directors3 independent2 executive
- Haseeb Ahmad Drabu · ChairpersonIndependent · joined Sep 2019 · reappointed Aug 2024 · 95 months as independent · 1 listed board · 1 as independent
- Nikunj Velji Mange · Managing directorExecutive · joined Aug 2020 · reappointed Aug 2026 · 2 months as independent · 1 listed board · 2 committee seats
- Manas Rajendra MengarIndependent · joined Aug 2023 · 38 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- Kiran Raghavendra AwasthiIndependent · joined Nov 2025 · 11 months as independent · 2 listed boards · 2 as independent · 1 committee seat, 1 as chair
- Vaibhav OdhekarExecutive · joined Aug 2026 · 1 listed board · 1 committee seat
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
4 directors who left
- Pankaj Jashwant Shah, left 3 Aug 2026: Others
- Alaka Keshav Deshpande, left 30 Dec 2025: Others
- Mangala RadhaKrishnan Prabhu, left 27 Sep 2025: Tenure Completion
- Avinash Chander Mahajan, left 22 Jan 2025: Others
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 12 Sep 20264 of 5 present2 independent · 30 days in between
- 12 Aug 20264 of 4 present3 independent · 80 days in between
- 23 May 20264 of 5 present2 independent
Audit Committee
Chair Kiran Raghavendra Awasthi
Nikunj Velji Mange, Manas Rajendra Mengar, Vaibhav Odhekar
- 12 Sep 20264 of 4 present2 independent · 30 days in between
- 12 Aug 20263 of 3 present2 independent · 80 days in between
- 23 May 20263 of 3 present2 independent
Nomination and remuneration committee
Chair Kiran Raghavendra Awasthi
Haseeb Ahmad Drabu, Manas Rajendra Mengar
- 12 Aug 20262 of 3 present2 independent · 80 days in between
- 23 May 20262 of 3 present2 independent
Stakeholders Relationship Committee
Chair Manas Rajendra Mengar
Kiran Raghavendra Awasthi, Nikunj Velji Mange
No meeting listed in the filing.
Right Issue Committee
Chair Nikunj Velji Mange
Kiran Raghavendra Awasthi, Vaibhav Odhekar
No meeting listed in the filing.
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Jun 2026.
- Sarda Soni Associates LLPPeer-review certificate valid to Oct 2026
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Aspira Pathlab & Diagnostics AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Aspira Pathlab & Diagnostics share news and announcements
Annual general meeting, 25 Sep 2026
1,623 shareholders on the register on 18 Sep 2026; present: 1 promoter and 27 others; votes counted by PRAJAKTA V PADHYE / NILESH A. PRADHAN & CO.LLP.The company's voting result (opens in a new tab)
- Adoption of audited standalone financial statements for the financial year ended 31st March, 2026 and the Directors' and Auditors' ReportOrdinary84.00% for16.00% against
Against: promoters 0.00% · institutions 0.00% · other public 16.00%
Turnout: all 0.00% · promoters 0.00% · institutions 0.00% · other public 0.00%
- Re-appointment of Mr. Nikunj V. Mange (DIN:08489442) as Director of the Company, liable to retire by rotation:OrdinaryPromoters have an interest in it84.00% for16.00% against
Against: promoters 0.00% · institutions 0.00% · other public 16.00%
Turnout: all 0.00% · promoters 0.00% · institutions 0.00% · other public 0.00%
- Approval of Related Party Transaction with M/s. Yashraj Research Foundation.OrdinaryPromoters have an interest in it84.00% for16.00% against
Against: promoters 0.00% · institutions 0.00% · other public 16.00%
Turnout: all 0.00% · promoters 0.00% · institutions 0.00% · other public 0.00%
- Re-designation of Executive Director Mr. Nikunj Velji Mange (DIN: 08489442) as "Managing Director" of the companySpecialPromoters have an interest in it84.00% for16.00% against
Against: promoters 0.00% · institutions 0.00% · other public 16.00%
Turnout: all 0.00% · promoters 0.00% · institutions 0.00% · other public 0.00%
- Regularization of the Appointment of Mr. Vaibhav Odhekar (Din: 05135001) As An Executive Director of the CompanySpecial84.00% for16.00% against
Against: promoters 0.00% · institutions 0.00% · other public 16.00%
Turnout: all 0.00% · promoters 0.00% · institutions 0.00% · other public 0.00%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Fines
Reported in the filing for the quarter to Sep 2026.
- Fine or penaltyDisrtict Court Bhiwandi and High CourtSince 28 Jul 2026
In the matter of Dr. Salima Arshad Rais v. Aspira Pathlab & Diagnostics Limited, proceedings are pending before the District Court in connection with a dispute arising out of a Leave and Licence Agreement. The Company had filed a Leave to Defend before the District Court, which was rejected. Aggrieved by the said order, the Company filed an appeal before the Hon’ble High Court. The Hon’ble High Court has granted ad-interim relief to the Company, subject to the deposit of 50% of the claim amount.
Dispute arising out of a Leave and Licence Agreement - Fine or penaltyDisrtict Court Bhiwandi and High CourtSince 28 Jul 2026
In the matter of Dr. Arshad Anwar Rais v. Aspira Pathlab & Diagnostics Limited, proceedings are pending before the District Court in connection with a dispute arising out of a Leave and Licence Agreement. The Company had filed a Leave to Defend before the District Court, which was rejected. Aggrieved by the said order, the Company filed an appeal before the Hon’ble High Court. The Hon’ble High Court has granted ad-interim relief to the Company, subject to the deposit of 50% of the claim amount.
Dispute arising out of a Leave and Licence Agreement - Fine or penaltyDisrtict Court Bhiwandi and High CourtSince 28 Jul 2026
In the matter of Dr. Sahil Arshad Rais v. Aspira Pathlab & Diagnostics Limited, proceedings are pending before the District Court in connection with a dispute arising out of a Leave and Licence Agreement. The Company had filed a Leave to Defend before the District Court, which was rejected. Aggrieved by the said order, the Company filed an appeal before the Hon’ble High Court. The Hon’ble High Court has granted ad-interim relief to the Company, subject to the deposit of 50% of the claim amount.
Dispute arising out of a Leave and Licence Agreement
In the company's own words, from its latest governance filing.
Investor complaints and compliance
Quarter by quarter.
Investor complaints received and resolved, the company's own count
- Received
- Resolved
Open at the quarter's end
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- No
- The filing has a part on fines and penalties
- Yes
- The filing has a part on tax disputes
- No
- There was a cyber security incident in the quarter
- No
The company's own answers in its filing.